Zelira Therapeutics Ltd's (ASX:ZLD) (OTCMKTS:ZLDAF) Dr Oludare Odumosu and Levin Health Limited's Mark Brayshaw discuss plans for its upcoming chronic pain clinical trial. Levin will use Zelira's ZTL-106 formulation for testing on retired athletes in a chronic pain treatment study at La Trobe University in Melbourne. The trial will be sponsored by Levin, which will pay Zelira to design and manage the study, while both companies will share any commercialisation profits.
Zelira Therapeutics and Levin Health talk upcoming chronic pain clinical trial
